StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.73−0.03 (-4.27%)

Close on Nov 18, 2026Market cap $2.15MP/E –Yield –

BioNexus Gene Lab free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

BioNexus Gene Lab's free cash flow for the twelve months ending Jun 30, 2026 was -$853.60K. For fiscal 2025 it was -$1.88M. The highest annual figure on record is $551.82K in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.88M–
FY2024Dec 31, 2024-$2.32M–
FY2023Dec 31, 2023-$1.97M-457.3%
FY2022Dec 31, 2022$551.82K+9098.6%
FY2021Dec 31, 2021$6.00K-95.4%
FY2020Dec 31, 2020$131.06K–
FY2019Dec 31, 2019-$230.09K–
FY2018Dec 31, 2018-$234.46K–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$422.74K–
Q1 FY2026Mar 31, 2026-$148.00K–
Q4 FY2025Dec 31, 2025$960.09K+346.2%
Q3 FY2025Sep 30, 2025-$1.24M–
Q2 FY2025Jun 30, 2025-$759.37K–
Q1 FY2025Mar 31, 2025-$833.12K–
Q4 FY2024Dec 31, 2024$215.18K–
Q3 FY2024Sep 30, 2024-$1.80M–
Q2 FY2024Jun 30, 2024-$674.11K–
Q1 FY2024Mar 31, 2024-$59.10K–
Q4 FY2023Dec 31, 2023-$783.46K-252.5%
Q3 FY2023Sep 30, 2023-$1.03M-438.5%
Q2 FY2023Jun 30, 2023-$38.18K–
Q1 FY2023Mar 31, 2023-$116.62K–
Q4 FY2022Dec 31, 2022$513.88K+6.7%
Q3 FY2022Sep 30, 2022$305.23K-3.2%
Q2 FY2022Jun 30, 2022-$197.26K–
Q1 FY2022Mar 31, 2022-$70.03K-161.1%
Q4 FY2021Dec 31, 2021$481.73K-5.8%
Q3 FY2021Sep 30, 2021$315.46K-58.2%
Q2 FY2021Jun 30, 2021-$905.81K–
Q1 FY2021Mar 31, 2021$114.62K–
Q4 FY2020Dec 31, 2020$511.17K–
Q3 FY2020Sep 30, 2020$754.74K–
Q2 FY2020Jun 30, 2020-$157.20K–
Q1 FY2020Mar 31, 2020-$977.66K–
Q4 FY2019Dec 31, 2019-$65.51K-125.1%
Q3 FY2019Sep 30, 2019-$53.88K-124.1%
Q2 FY2019Jun 30, 2019-$76.77K–
Q1 FY2019Mar 31, 2019-$33.93K–
Q4 FY2018Dec 31, 2018$261.08K–
Q3 FY2018Sep 30, 2018$223.33K–

More BioNexus Gene Lab figures

See a number that looks wrong?